SMBA1, a Bax Activator, Induces Cell Cycle Arrest and Apoptosis in Malignant Glioma Cells

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with limited treatment options.
• Small-molecule Bax agonists 1 (SMBA1) are known activators of Bax, a key protein in apoptosis.
• Identifying novel therapeutic agents for GBM is a critical unmet need.

Purpose of the Study:

• To investigate the anti-tumour effects of SMBA1 on glioblastoma (GBM) cells.
• To elucidate the mechanism of action of SMBA1 in GBM.
• To evaluate the in vivo efficacy of SMBA1 against GBM xenografts.

Main Methods:

• Cell viability assays (MTT) were performed on U87MG, U251, and T98G GBM cell lines.
• Cell cycle analysis and Western blotting were used to assess cell cycle progression and protein expression (Cdc25c, cyclin B1, p21).
• Apoptosis induction was measured, and the role of Bax and Bcl-2 was investigated through gene silencing and overexpression studies. In vivo studies utilized U87MG xenograft models.

Main Results:

• SMBA1 demonstrated a time- and dose-dependent reduction in GBM cell viability.
• SMBA1 induced G2/M phase cell cycle arrest, characterized by decreased Cdc25c and cyclin B1, and increased p21 expression.
• SMBA1 triggered apoptosis via the intrinsic pathway, which was Bax-dependent and could be modulated by Bcl-2. In vivo, SMBA1 significantly inhibited U87MG xenograft tumor growth.

Conclusions:

• SMBA1 exhibits significant anti-proliferative and pro-apoptotic effects on glioblastoma cells in vitro and in vivo.
• The anti-tumour activity of SMBA1 is mediated through the activation of the intrinsic apoptosis pathway.
• SMBA1 represents a promising therapeutic candidate for the treatment of glioblastoma.